Heine H. Hansen Award Goes to Suresh Senan
The award will be presented at the European Lung Cancer Conference (ELCC) 2016, held 13 to 16 April in Geneva, Switzerland.
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
The award will be presented at the European Lung Cancer Conference (ELCC) 2016, held 13 to 16 April in Geneva, Switzerland.
The latest article to appear on ESMO Open highlights ESMO’s hope that the 2015 WHO Model List of Essential Medicines (EML) will empower oncologists and advocates to demand routine availability of the medicines considered essential to guarantee quality care of cancer patients
Creation of CMO role reflects ESMO’s rapid growth and follows extensive six-month selection process
On World Cancer Day, ESMO puts cancer patients centre stage by organising a workshop dedicated to exploring ways that advocacy networks can drive research
ESMO announces the appointment of Keith Hanson McGregor as their new CEO. Dr McGregor is currently ESMO’s Chief Operating Officer.
KEYNOTE-010 data further supports broadening pembrolizumab availability for all advanced NSCLC patients with PD-L1 expression over 1%
LUX-Lung 7 trial reveals that the second-generation EGFR tyrosine kinase inhibitor significantly improved PFS in naive patients with advanced mutated lung cancer compared to gefitinib
Promising results of PALOMA3 trial confirmed in Asian patients
Phase I trial reports that pembrolizumab is active in nasopharyngeal cancer. Afatinib is effective as second-line treatment in squamous cell carcinoma of the head and neck in a Phase II study
Underprivileged patients are at major risk of disease-related “financial catastrophe", study in eight low- and middle-income Southeast Asian countries shows
LUGANO/SINGAPORE, 16 December 2015 – ESMO, the leading professional organisation for medical oncology, is pleased to announce the inaugural ESMO Asia 2015 Congress in Singapore. A premier scientific and educational platform for oncologists and other stakeholders in cancer care, the Asian edition of ESMO’s annual congress aims to facilitate information exchange between researchers, clinicians and patients across disciplines to find the most effective treatment solutions.
CheckMate 017 clearly showed that the checkpoint inhibitor improves the overall health status in patients with advanced squamous non-small-cell lung cancer
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.